TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Syros Pharmaceuticals ( (SYRS) ) has shared an announcement.
Syros Pharmaceuticals faces significant challenges as it terminates its collaboration with QIAGEN, following the failure of its SELECT-MDS-1 Phase 3 trial to meet key endpoints. This resulted in a default under its Loan Agreement with Oxford Finance, demanding nearly $43.7 million repayment. In response, Syros has initiated a drastic workforce reduction of 94% to curb costs and maximize stakeholder value, highlighting its ongoing financial struggles.
See more insights into SYRS stock on TipRanks’ Stock Analysis page.